Rare ovarian tumours. Other treatments for ovarian cancer

• Main Authors: Marta Gil-Martin, Beatriz Pardo, Maria-Pilar Barretina-Ginesta
• Format: Article
• Language: English
• Published: Elsevier 2020-08-01
• Series: EJC Supplements
• Subjects: Rare malignant ovarian tumours; Hormonotherapy; Targeted therapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S1359634919300035

Aim: The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained. Methods: Literature review and ongoing trial information have been used to elaborate this guide. Results: Each ovarian cancer type must be identified and treated properly from diagnostic to surgery, adjuvant treatment and metastatic disease. Hormonotherapy can be useful as an alternative treatment, especially in low-grade ovarian cancer and endometrioid subtype. Tumour characterisation is appropriated for treatment selection when targeted therapy is indicated. MEK inhibitors, tyrosine-kinase inhibitors, EGFR inhibitors, therapies against integrins, antibody–drug conjugates and other strategies are described. Antiangiogenics, PARP inhibitors and immunotherapy are discussed in other parts of this publication. Conclusion: Different ovarian cancer types must receive the appropriated treatment. Alternative therapies may be evaluated beyond the standard therapy, frequently in a clinical trial, and an individualised molecular study may help to find the best treatment.